Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease
| Autor: | Jasper J. N. Sangen, Mike Marvin Ruth, Jodie A. Schildkraut, Jakko van Ingen, Heiman F. L. Wertheim, Cecile Magis-Escurra, Wouter Hoefsloot, Lian J. Pennings |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Lung Diseases
0301 basic medicine Intravenous treatment Continuation Phase 030106 microbiology Pulmonary disease Minocycline Microbial Sensitivity Tests Disease Mycobacterium abscessus Pharmacology 03 medical and health sciences 0302 clinical medicine Pharmacokinetics medicine Pharmacology (medical) 030212 general & internal medicine biology business.industry biology.organism_classification bacterial infections and mycoses Anti-Bacterial Agents lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Infectious Diseases Susceptibility Treatment modality bacteria business medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy, 62, e01208-18 Antimicrobial Agents and Chemotherapy, 62, 10, pp. e01208-18 |
| ISSN: | 0066-4804 |
| Popis: | Item does not contain fulltext Mycobacterium abscessus causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined the MICs, synergy, and time-kill kinetics of minocycline against M. abscessus With MICs of 8 to 512 mg/liter, rapid emergence of tolerance in time-kill assays, and no synergy with other drugs used to treat MAb-PD, minocycline appears ineffective against M. abscessus These in vitro data question its role as a MAb-PD treatment modality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|